Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: Preliminary results

Pediatric Hematology and Oncology

Volumn 14, Issue 3, 1997, Pages 213-222

  Schiavetti, A ^a   Castello, M A ^a,b   Versacci, P ^a   Varrasso, G ^a   Padula, A ^a   Ventriglia, F ^a   Werner, B ^a   Colloridi, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Istituto di Clinica Pediatrica   (Italy)

Author keywords

anthracycline; cardiotoxicity; ICRF 187

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; RAZOXANE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART PROTECTION; HEPATOBLASTOMA; HUMAN; INFANT; MALE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA;

EID: 0030998937     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019709009491     Document Type: Article

References (30)

1. Gilladoga AC, Manuel C, Tan CTC, et al. The cardiotoxicity of Adriamycin and daunomycin in children. Cancer. 1976;37:1070-1078.
2. Pratt CB, Ransom JL, Evans WE. Age related Adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;63:827-834.
3. Von Hoff DD, Layard M, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med. 1979;91:701-717.
4. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
5. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
6. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics. 1992;89:942-949.
7. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139.
8. Breed JGS, Zimmerman ANE, Dormans JAMA, et al. Failure of the antioxidant vitamin E to protect against Adriamycin induced cardiotoxicity in the rabbit. Cancer Res. 1980;40:2033-2038.
9. Doroshow JH, Locker GY, Ifrim I, et al. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981;68:1053-1064.
10. Herman E, Ferrans VJ, Young R, et al: Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 1988;48:6918-6925.
11. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319: 745-752.
12. Speyer J, Green M, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-127.
13. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362-372.
14. Basser R, Duggan G, Rosenthal MA, et al. Optimal dose ratio of ADR-529 (ICRF-187) and epirubicin. Proc Am Soc Clin Oncol. 1992;11:123.
15. Tan CT, Tasaka H, Yu K-P, et al. Daunomycin: an antitumor antibiotic in the treatment of neoplastic disease. Cancer. 1967;20:333-353.
16. Lenaz L, Page JA. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3: 111-120.
17. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986;46:3722-3727.
18. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8:1806-1810.
19. Italian multicentre breast study with epirubicin: phase III randomized study of fluoracil, epirubicin and cyclophosphamide v fluororacil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988;6:976-982.
20. Pegelow CH, Popper RW, DeWit SA, et al. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol. 1984;2:443-446.
21. Weesner KM, Bledsoe M, Chauvenet A, et al: Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68:435-438.
22. Bloom K, Bini R, Williams C, et al. Echocardiography in Adriamycin cardiotoxicity. Cancer. 1978; 41:1265-1269.
23. Bu'Lock FA, Martin RP, Oakill A, et al. Early identification of patients with significant anthracycline cardiotoxicity: potential for prevention of late sequelae. Med Pediatr Oncol. 1995;3:187. Abstract.
24. Lipshultz SE, Colan SD: The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. In: Bricker JT, Green DM, D'Angio GJ, eds. Cardiac Toxicity After Treatment for Childhood Cancer. New York: Wiley-Liss; 1993:45-62.
25. Herman EH, Ferrans VJ. Pathophysiology of anthracycline cardiotoxicity. In: Bricker JT, Green DM, D'Angio GJ, eds. Cardiac Toxicity After Treatment for Childhood Cancer. New York: Wiley-Liss; 1993:25-34.
26. Haasinoff BB. The interaction of the cardioprotective agent ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane); its hydrolysis product (ICRF 198); and other chelating agents with the Fe (III) and Cu (II) complexes of Adriamycin. Agents Actions. 1990;29:374-381.
27. Wadler S, Green MD, Muggia FM. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5dioxopiperazinyl-1-yl) propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res. 1986;46:1176-1181.
28. Bu'Iock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. 1993;70:185-188.
29. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114-1118.
30. Legha SS, Benjamin RS, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982;49:1762-1766.